Hofseth Biocare ASA announced that Strengthens R&D Function with the Hiring of Dr. Erland Hermansen as Medical Director for Clinical Development. Dr. Hermansen is a qualified Orthopaedic surgeon based in Alesund, Norway where he was Head of the Surgical department Ålesund Hospital, Møre and Romsdal Hospital Trust. He has extensive experience in reconstructive joint and spine surgery combined with large scale clinical trial work including his role as Project administrator for the 1,000 patient NORDSTEN-study for the surgical management of spinal stenosis. Dr. Hermansen's deep understanding of the musculoskeletal system and clinical trial delivery makes him ideal for the role of Medical Director for Clinical Development at HBC. HBC’s marine bone powder CalGo is set to enter clinical development following preclinical work which has shown marked differentiation from other forms of calcium replacement, both for bone mass and strength. In addition to the planned work in bone health (osteoporosis) and joint health (osteoarthritis). Dr. Hermansen is excited by the potential for CalGo in other orthopaedic settings and preclinical work in these areas is set to commence imminently.